Alligator Bioscience: Surprise, surprise! - SEB

Monday, February 10, 2020 8:44 AM
"Ahead Q4, we revisit our assumptions for a potential licensing deal for ATOR-1017 which trigger significant estimates changes for 2020-21. Alligator’s cash position after Q3 was SEK 302m, which management expects to last into Q1 2021, but given the likely delay in ATOR-1017, we assume it will need a new rights issue during 2020. Our revised valuation range is SEK 17-21 per share, with upside if a deal can be secured sooner."

Link to commissioned research below.